

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50701/003002
	Serial No.	09/699,003
	Applicant	Lentz
	Filing Date	October 26, 2000
	Group	3761
	IDS Filed	March 5, 2010

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Decision – Interlocutory Motion – Bd.R.123(b), Before the Board of Patent Appeals and Interferences, United States Patent and Trademark Office, Paper 125, May 22, 2007, at 2.
	Decision on Motions, Before the Board of Patent Appeals and Interferences, United States Patent and Trademark Office, Paper 108, filed January 25, 2007 (1-53).
	Decision-Priority-Bd.R. 125(a), Before the Board of Patent Appeals and Interferences, United States Patent and Trademark Office, Paper 155, filed January 9, 2008 (1-21).
	Declaration under 37 C.F.R. 1.131 of Dr. Rigdon Lentz, filed February 4, 2005.
	Selinsky et al., "Multifaceted Inhibition of Anti-Tumor Immune Mechanisms by Soluble Tumor Necrosis Factor Receptor Type I," <i>Immunology</i> 94:88-93, 1998.
	Transcript of Oral Hearing, November 20, 2007, Paper 151, at 37, II. 4-8.
	Transcript of Oral Hearing, November 20, 2007, Paper 151, at 38, II. 11-13.
	Transcript of Oral Hearing, November 20, 2007, Paper 151, at 37, II. 4-8; at 38, II. 11-17.

EXAMINER	/Leslie Deak/	DATE CONSIDERED	03/25/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LD/